This Article  • Full text  • PDF  • CME Course for This Article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Diabetes Mellitus  • Renal Diseases  • Renal Diseases, Other  • Hypertension  • Arrhythmias  • Cardiovascular Disease/ Myocardial Infarction  • Congestive Heart Failure/ Cardiomyopathy  • Adverse Effects  • Alert me on articles by topic

Treat Now by Treating Comorbidities

Sanjiv J. Shah, MD; Mihai Gheorghiade, MD

JAMA. 2008;300(4):431-433.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Heart failure (HF) is a major public health problem, with a prevalence of more than 5 million cases and an incidence of 660 000 new cases per year in the United States alone.¹Among patients older than 65 years, HF has become the most common discharge diagnosis and the primary cause of readmission within 60 days of discharge, resulting in estimated costs of $34.8 billion per year.¹ Nearly half of all patients with HF have a preserved ejection fraction (HFPEF).^2-5 Patients with HFPEF have a high all-cause mortality after hospitalization for HF: 2.9%, in-hospital mortality⁴; 9.5%, 60- to 90-day mortality⁴; 22% to 29%, 1-year mortality^2-3; and 65%, 5-year mortality.^2-3 These data underscore the urgent need to find ways to improve outcomes for these patients.

Unlike patients with HF and reduced ejection fraction, few large randomized controlled trials have been . . . [Full Text of this Article]

Author Affiliations: Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.